Weekly Recap | INNOCARE -4.21%, two pipeline milestones hitWeekly Review·Nov 14, 2026 at 07:28 AM09969-2.43%
Guoyuan Securities (HK) Remains a Buy on InnoCare Pharma Ltd. (9969)Tip Ranks·Nov 12, 2026 at 05:15 AM09969-2.43%688428-1.06%
InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in ChinaPUBT·Nov 11, 2026 at 01:48 PM09969-2.43%688428-1.06%
InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AMLPUBT·Nov 9, 2026 at 01:33 AM09969-2.43%688428-1.06%
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary EndpointMorningStar·Nov 5, 2026 at 10:48 AM09969-2.43%688428-1.06%
China Accepts InnoCare’s Orelabrutinib Application for ITP TreatmentPUBT·Nov 5, 2026 at 10:35 AM09969-2.43%688428-1.06%
InnoCare Doses First Subject in Phase 1 Trial of Autoimmune Drug ICP-B161 in ChinaPUBT·Oct 30, 2026 at 02:02 AM09969-2.43%688428-1.06%
CMBI Raises INNOCARE TP to HKD18.9, Maintains Buy RatingAASTOCKS News·Oct 29, 2026 at 08:20 AM09969-2.43%688428-1.06%
InnoCare Pharma (SEHK:9969) Climbed, What Is Driving Attention Today?Simplywall·Oct 29, 2026 at 05:06 AM09969-2.43%688428-1.06%
INNOCARE Rises Over 5% as G Sachs Raises TP to HKD23.16AASTOCKS News·Oct 28, 2026 at 05:40 AM09969-2.43%688428-1.06%
InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma TrialPUBT·Oct 28, 2026 at 12:30 AM09969-2.43%688428-1.06%
InnoCare Pharma Reports Strong Orelabrutinib Data at ESMOTradingView·Oct 28, 2026 at 12:30 AM09969-2.43%688428-1.06%
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating GlobalizationMorningStar·Oct 26, 2026 at 10:47 AM09969-2.43%
M Stanley: Outlook for 4Q26 Catalysts in China Biotech Stocks; Sector Rated "Attractive"AASTOCKS News·Oct 23, 2026 at 05:35 AM01801-2.68%02162-1.68%